

9 November 2022

Original: English

(22-8369) Page: 1/2

Committee on Import Licensing

AGREEMENT ON IMPORT LICENSING PROCEDURES

NOTIFICATION UNDER ARTICLE 5.1 TO 5.4 OF THE AGREEMENT¹

MACAO, CHINA

The following notification, dated 24 October 2022, is being circulated at the request of the delegation of Macao, China.

	Category	Notification details
1	Notifying Member	Macao, China
2	Title of new legislation/procedure	 Chief Executive's Decision No. 209/2021 Organization and functioning of the Pharmaceutical Administration Bureau (Administrative Regulation No. 35/2021)
3	Date of Publication	 31 December 2021 25 October 2021
4	Date of entry into force	All effective from 1 January 2022
5	Website link/Official publication of the new regulation/procedure	 https://images.io.gov.mo/bo/i/2021/52/despce-209-2021.pdf https://images.io.gov.mo/bo/i/2021/43/rega-35-2021.pdf
6	Have you attached a copy of the regulation (PDF) to the Secretariat	[✓] Yes. (Please attach a copy of the regulation to the notification.) [] No.
7	Type of notification	 [] (a) New licensing regulation/procedure²; (please answer question 8 to 14) [√] (b) Changes to a regulation/procedure which has been previously notified in document: G/LIC/N/1/MAC/7; (please answer question 15 and 16)
8	List of products subject to licensing	Please provide the HS codes and detailed descriptions of the products. In case of a long list, please attach the list as an Annex in MS WORD document.
9	Nature of licensing	Automatic: []
		Non-Automatic: []
10	Administrative purpose/measure being implemented	 (a) Protect public morals; (b) Protect human, animal or plant life and health; protect environment; (c) Collect trade statistics or market surveillance;
		 (d) Protection of patents, trademarks and copyrights, and the prevention of deceptive practices; (e) Pursue obligations under the UN Charter and other international treaties (i.e. CITES, Basel Convention, Rotterdam Convention, UNSC Resolutions etc.)

 $^{^{1}}$ It is understood that the notifying Member has also completed its notification obligations under Article 1.4(a) and Article 8.2(b) regarding the relevant law/regulation/procedure notified for by filling this form in a full and complete manner.

² "New licensing regulation/procedure" is understood to refer to any newly introduced law, regulation or procedure, and those which are in force but being notified for the first time to the Committee.

	Category	Notification details
		(f) Quota (including TRQ) administration;
		(g) Regulate imports of arms, ammunition or fissionable materials and safeguard national security;
		(h) Other: (please specify)
11	Administrative body(ies) for submission of applications	
12	Contact point for information on eligibility	
13	Expected duration of licensing procedure	
14	A summary of the notification in one of the WTO official languages	
15	In the case of 7(b), please	(a) Termination
	indicate the type of new change(s)	(b) Suspension
	- Cina3-(-)	(c) Modification of specific details in existing procedures:
		Product coverage;
		Administrative purpose;
		☐ Automatic or Non-automatic;
		☐ Duration of licensing;
		☐ Change the nature of quantity/value restriction;
		Eligibility of applicants;
		Contact information on eligibility;
		Administrative body(ies) for submission of application;
		☐ Documentation requirements (including application form);
		Period for Application;
		Administrative body(ies) to issue licence;
		Processing time for issuing licence;
		Licence fee/administrative charge;
		Deposit/advance payment and relevant conditions;
		Appeal regulations/procedures;Validity of licence;
		Other conditions of licence (extension, transferability,
		penalty of non-use etc.);
		☐ Foreign exchange requirements;
		Other: (please specify).
16	Please elaborate the changes in detail (in one of the WTO official languages)	1. Chief Executive's Decision No. 209/2021 divides group B of Table B referred to in Paragraph 4, Article 9 of Law No. 7/2003 into B1 and B2, and includes toxic Chinese medicinal materials, prepared portions or extracts and general Chinese medicinal materials, prepared portions or extracts in group B1.
		2. According to Administrative Regulation No. 28/2003 as revised by Administrative Regulation No. 19/2016 and Administrative Regulation No. 35/2021, the authority to issue import licenses for goods listed in group B1 of Table B is vested in the Pharmaceutical Administration Bureau